Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Iterion Therapeutics
2450 Holcombe Blvd
Houston, TX 77021

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear beta-catenin, a historically "undruggable" oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors.

Key Contact
Rahul Aras, Ph.D.
Funding Events

02/16/21 $17,000,000 Series B GPG Ventures
Lumira Ventures
Sante Ventures
Venture Investors
Viva BioInnovator

Featured Reading